Melanoma CSCs often harbor mutations in such genes as BRAF and NRAS, which are associated with resistance mechanisms, including the reactivation of mitogen-activated protein kinases (MAPK) signaling pathways [108]. The gene discussed is BRAF; the disease is melanoma.